IL281043A - Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry - Google Patents
Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicryInfo
- Publication number
- IL281043A IL281043A IL281043A IL28104321A IL281043A IL 281043 A IL281043 A IL 281043A IL 281043 A IL281043 A IL 281043A IL 28104321 A IL28104321 A IL 28104321A IL 281043 A IL281043 A IL 281043A
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- vasculogenic mimicry
- inhibiting vasculogenic
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/083—Neurotensin
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722726P | 2018-08-24 | 2018-08-24 | |
| US201962804063P | 2019-02-11 | 2019-02-11 | |
| PCT/CA2019/051170 WO2020037434A1 (en) | 2018-08-24 | 2019-08-26 | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL281043A true IL281043A (en) | 2021-04-29 |
Family
ID=69591094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL281043A IL281043A (en) | 2018-08-24 | 2021-02-23 | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220000971A1 (https=) |
| EP (1) | EP3844190A4 (https=) |
| JP (1) | JP7592320B2 (https=) |
| CN (1) | CN113286820B (https=) |
| AU (1) | AU2019324747A1 (https=) |
| CA (1) | CA3110414A1 (https=) |
| IL (1) | IL281043A (https=) |
| WO (1) | WO2020037434A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107708733B (zh) | 2015-04-07 | 2022-11-15 | 艾利妥 | 抗分拣蛋白抗体和其使用方法 |
| CA3006313C (en) | 2015-11-24 | 2020-02-11 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| TWI809147B (zh) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | 抗分揀蛋白抗體及其使用方法 |
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN119403786A (zh) | 2022-06-23 | 2025-02-07 | 德罗普尼尔生物有限公司 | 选择性诱导细胞外靶标在溶酶体中降解的双功能分子 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| WO2025208212A1 (en) * | 2024-04-02 | 2025-10-09 | Theratechnologies Inc. | Combination therapies comprising peptide-drug conjugates targeting sortilin |
| WO2025236098A1 (en) * | 2024-05-16 | 2025-11-20 | Theratechnologies Inc. | Peptide conjugates of maytansinoids and uses thereof |
| WO2026021513A1 (zh) * | 2024-07-25 | 2026-01-29 | 上海湃鸿生物科技有限公司 | 一种多肽药物偶联物及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016270874B2 (en) * | 2015-06-03 | 2018-12-06 | Tairx, Inc. | Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry |
| CA3006313C (en) * | 2015-11-24 | 2020-02-11 | Transfert Plus, S.E.C. | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
-
2019
- 2019-08-26 US US17/270,787 patent/US20220000971A1/en active Pending
- 2019-08-26 CA CA3110414A patent/CA3110414A1/en active Pending
- 2019-08-26 AU AU2019324747A patent/AU2019324747A1/en active Pending
- 2019-08-26 EP EP19852741.8A patent/EP3844190A4/en active Pending
- 2019-08-26 WO PCT/CA2019/051170 patent/WO2020037434A1/en not_active Ceased
- 2019-08-26 JP JP2021534405A patent/JP7592320B2/ja active Active
- 2019-08-26 CN CN201980069301.0A patent/CN113286820B/zh active Active
-
2021
- 2021-02-23 IL IL281043A patent/IL281043A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021535209A (ja) | 2021-12-16 |
| CN113286820B (zh) | 2025-04-08 |
| JP7592320B2 (ja) | 2024-12-02 |
| AU2019324747A1 (en) | 2021-04-01 |
| WO2020037434A1 (en) | 2020-02-27 |
| CN113286820A (zh) | 2021-08-20 |
| EP3844190A4 (en) | 2022-06-08 |
| CA3110414A1 (en) | 2020-02-27 |
| EP3844190A1 (en) | 2021-07-07 |
| US20220000971A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281043A (en) | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| IL304835A (en) | Oxadiazole trp channel inhibitors | |
| PT3814341T (pt) | Inibidores de recetor erbb | |
| IL277006A (en) | CD73 inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| IL304348A (en) | cd73 inhibitors | |
| SG11202105711SA (en) | Rnai constructs for inhibiting pnpla3 expression | |
| IL277970A (en) | Compounds and Methods for Reducing FXI Expression | |
| IL281815A (en) | VAP-1 inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202103776YA (en) | Apparatus for delivery of radioembolization microspheres | |
| IL283627A (en) | Improved transport of large materials | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| GB2581127B (en) | Protection apparatus | |
| ZA202101964B (en) | Combustion apparatus | |
| GB201817672D0 (en) | Combustion effect apparatus | |
| HK40052673A (en) | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry | |
| PL3643704T3 (pl) | Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu | |
| IL284752A (en) | Cb1r receptor blockers with acyclic backbones | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201910526D0 (en) | Antagonist | |
| GB201909500D0 (en) | Antagonist | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors |